These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Mitochondrial optic neuropathies: how two genomes may kill the same cell type? Carelli V; La Morgia C; Iommarini L; Carroccia R; Mattiazzi M; Sangiorgi S; Farne' S; Maresca A; Foscarini B; Lanzi L; Amadori M; Bellan M; Valentino ML Biosci Rep; 2007 Jun; 27(1-3):173-84. PubMed ID: 17479363 [TBL] [Abstract][Full Text] [Related]
9. PMPCA-Related Encephalopathy: Novel Variants, Phenotype Extension, and Mitochondrial Morphology. Rambani V; Kolnikova M; Cagalinec M; Skopkova M; Gasperikova D Neurol Genet; 2023 Dec; 9(6):e200106. PubMed ID: 38235041 [TBL] [Abstract][Full Text] [Related]
10. OPA1 gene therapy prevents retinal ganglion cell loss in a Dominant Optic Atrophy mouse model. Sarzi E; Seveno M; Piro-Mégy C; Elzière L; Quilès M; Péquignot M; Müller A; Hamel CP; Lenaers G; Delettre C Sci Rep; 2018 Feb; 8(1):2468. PubMed ID: 29410463 [TBL] [Abstract][Full Text] [Related]
11. Dominant mutations in MIEF1 affect mitochondrial dynamics and cause a singular late onset optic neuropathy. Charif M; Wong YC; Kim S; Guichet A; Vignal C; Zanlonghi X; Bensaid P; Procaccio V; Bonneau D; Amati-Bonneau P; Reynier P; Krainc D; Lenaers G Mol Neurodegener; 2021 Feb; 16(1):12. PubMed ID: 33632269 [TBL] [Abstract][Full Text] [Related]
12. Mutations in DNM1L, as in OPA1, result in dominant optic atrophy despite opposite effects on mitochondrial fusion and fission. Gerber S; Charif M; Chevrollier A; Chaumette T; Angebault C; Kane MS; Paris A; Alban J; Quiles M; Delettre C; Bonneau D; Procaccio V; Amati-Bonneau P; Reynier P; Leruez S; Calmon R; Boddaert N; Funalot B; Rio M; Bouccara D; Meunier I; Sesaki H; Kaplan J; Hamel CP; Rozet JM; Lenaers G Brain; 2017 Oct; 140(10):2586-2596. PubMed ID: 28969390 [TBL] [Abstract][Full Text] [Related]
13. Not only dominant, not only optic atrophy: expanding the clinical spectrum associated with OPA1 mutations. Nasca A; Rizza T; Doimo M; Legati A; Ciolfi A; Diodato D; Calderan C; Carrara G; Lamantea E; Aiello C; Di Nottia M; Niceta M; Lamperti C; Ardissone A; Bianchi-Marzoli S; Iarossi G; Bertini E; Moroni I; Tartaglia M; Salviati L; Carrozzo R; Ghezzi D Orphanet J Rare Dis; 2017 May; 12(1):89. PubMed ID: 28494813 [TBL] [Abstract][Full Text] [Related]
14. Dominant optic atrophy: updates on the pathophysiology and clinical manifestations of the optic atrophy 1 mutation. Chun BY; Rizzo JF Curr Opin Ophthalmol; 2016 Nov; 27(6):475-480. PubMed ID: 27585216 [TBL] [Abstract][Full Text] [Related]
15. Emerging Mitochondrial Therapeutic Targets in Optic Neuropathies. Lopez Sanchez MI; Crowston JG; Mackey DA; Trounce IA Pharmacol Ther; 2016 Sep; 165():132-52. PubMed ID: 27288727 [TBL] [Abstract][Full Text] [Related]
16. OPA1 haploinsufficiency induces a BNIP3-dependent decrease in mitophagy in neurons: relevance to Dominant Optic Atrophy. Moulis MF; Millet AM; Daloyau M; Miquel MC; Ronsin B; Wissinger B; Arnauné-Pelloquin L; Belenguer P J Neurochem; 2017 Feb; 140(3):485-494. PubMed ID: 27861891 [TBL] [Abstract][Full Text] [Related]
17. Mutations in the substrate binding glycine-rich loop of the mitochondrial processing peptidase-α protein (PMPCA) cause a severe mitochondrial disease. Joshi M; Anselm I; Shi J; Bale TA; Towne M; Schmitz-Abe K; Crowley L; Giani FC; Kazerounian S; Markianos K; Lidov HG; Folkerth R; Sankaran VG; Agrawal PB Cold Spring Harb Mol Case Stud; 2016 May; 2(3):a000786. PubMed ID: 27148589 [TBL] [Abstract][Full Text] [Related]
18. Mitochondrial dysfunction as a cause of optic neuropathies. Carelli V; Ross-Cisneros FN; Sadun AA Prog Retin Eye Res; 2004 Jan; 23(1):53-89. PubMed ID: 14766317 [TBL] [Abstract][Full Text] [Related]